Healthcare / Medical DevicesKOSDAQ
$8730.00
-30.00 (-0.34%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $2.0B · quality 48.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
42/100
C
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
12/100
SEC 0%
Sin guardar todavía.
Market Cap
$44.6B
P/E
7.5x
↓EV/EBITDA
5.8x
↓ROE
8.3%
↑Gross Margin
41.9%
↓Debt/Equity
0.19
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2023–2025 · 2 años de histórico normalizado
Revenue CAGR
+3.3%
FCF CAGR
-25.2%
FCF margin
4.2%
FCF / Net income
0.39x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $48.47B · net income $5.26B · FCF $2.05B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | $48.47B | $48.47B | $45.05B | $45.41B |
| Net Income | $5.26B | $5.26B | $6.04B | $6.61B |
| EBITDA | $7.57B | $7.57B | $8.51B | $9.37B |
| EPS | 1168.00 | 1168.00 | 1452.00 | 1589.00 |
| Gross Margin | 41.9% | 41.9% | 43.5% | 42.2% |
| Operating Margin | 10.0% | 10.0% | 8.7% | 14.5% |
| Net Margin | 10.8% | 10.8% | 13.4% | 14.6% |
| Balance Sheet | ||||
| Debt/Equity | 0.19 | 0.19 | 0.39 | 0.23 |
| Current Ratio | 7.04 | 7.04 | — | — |
| Cash Flow | ||||
| Free Cash Flow | $2.05B | $2.05B | $-7.40B | $3.66B |
| Returns | ||||
| ROE | 8.3% | 8.3% | 14.6% | 17.9% |
| Valuation | ||||
| P/E | 7.47 | 7.47 | — | — |
| EV/EBITDA | 5.78 | 5.78 | — | — |
| P/B | 0.62 | 0.62 | — | — |
| Growth & Yield | ||||
| Revenue Growth | 7.6% | 7.6% | -0.8% | — |
| EPS Growth | -19.6% | -19.6% | -8.6% | — |
| Dividend Yield | 2.8% | 2.8% | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
-12.8%
EPS terminal req.
$774.64
Spread vs growth
-6.8%
5Y implied EPS CAGR
-4.3%
EPS terminal req.
$937.32
Spread vs growth
-15.3%
10Y implied EPS CAGR
2.6%
EPS terminal req.
$1509.56
Spread vs growth
-22.2%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-44.9%
Start / end P/E
11.5x → 7.5x
EPS bridge
1452.00 → 1168.00
Residual
+6.9%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.